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Medicine and Surgery, Federico II University. PAbstract Background and aim: The objective of this cross-sectional study was to evaluate the
degree of glycaemic control and the frequency of diabetic complications in Italian people
with diabetes who were treated with continuous subcutaneous insulin infusion (CSII).
Methods and results: Questionnaires investigating the organisation of diabetes care centres,
individuals’ clinical and metabolic features and pump technology and its management were sent
to adult and paediatric diabetes centres that use CSII for treatment in Italy. Information on
standard clinical variables, demographic data and acute and chronic diabetic complications
was derived from local clinical management systems. The sample consisted of 6623 people with
diabetes, which was obtained from 93 centres. Of them, 98.8% had type 1 diabetes mellitus, 57.2%
were female, 64% used a conventional insulin pump and 36% used a sensor-augmented insulin
pump. The median glycated haemoglobin (HbA1c) level was 60 mmol/mol (7.6%). The HbA1c
target (i.e. <58 mmol/mol for age <18 years and <53 mmol/mol for age >18 years) was achieved
in 43.4% of paediatric and 23% of adult participants. Factors such as advanced pump functions,
higher rate of sensor use, pregnancy in the year before the study and longer duration of diabetes
were associated with lower HbA1c levels.
The most common chronic complications occurring in diabetes were retinopathy, microalbu-
minuria and hypertension. In the year before the study, 5% of participants reported 1 episode of
severe hypoglycaemic (SH) episodes (SH) and 2.6% reported 1 episode of ketoacidosis.
Conclusions: Advanced personal skills and use of sensor-based pump are associated with better
metabolic control outcomes in Italian people with diabetes who were treated with CSII.
The reduction in SH episodes confirms the positive effect of CSII on hypoglycaemia.
Clinical trial registration number: NCT 02620917 (ClinicalTrials.gov).f Medicine, University Hospital of Padova, Via Giustiniani 2, 35128, Padova, Italy.
unipd.it (D. Bruttomesso).
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In the past 25 years, continuous subcutaneous insulin
infusion (CSII) has become a viable alternative to multiple
daily insulin injections (MDIs) in people with type 1 dia-
betes mellitus (T1DM). Meta-analyses of both randomised
controlled trials (RCTs) and observational studies have
found lower glycated haemoglobin (HbA1c) level, less
severe hypoglycaemic (SH) episodes and a better quality of
life in people on CSII than those on MDI [1e3]. The limi-
tations of these reviews, however, are the inclusion of
MDI-treated individuals who do not use basal insulin
analogue and CSII-treated individuals who use regular
insulin. Recent studies comparing treatments with CSII
and MDI along with insulin analogue showed less evident
benefits for CSII [4,5].
A sensor-augmented insulin pump (SAP) is an insulin
pump that has the feature of continuous glucose moni-
toring (CGM). RCTs have shown that SAPs improve
metabolic control without increasing SH episodes in in-
dividuals with T1DM with elevated HbA1c levels, and SAPs
reduce the frequency and duration of hypoglycaemic
events in individuals with satisfactory glucose control
[6e8]. Recent studies have also suggested the protective
role of CSII against chronic diabetic complications and
cardiovascular mortality [9e13].
In 2013, we performed a survey on CSII in Italy and
addressed the organisation of diabetes centres and care
recipients and device characteristics [14]. Factors such
as quality of glycaemic control and acute and chronic
metabolic complications were not considered in that
survey. In this study, we report a new survey to investigate
metabolic control and diabetic complications in
CSII-treated individuals in Italy.Methods
Study design
In this multicentre cross-sectional study, data were
collected using questionnaires sent by e-mail to adult and
paediatric diabetes care centres that use CSII for treatment.
Centres were identified from previous surveys and
through information from companies selling CSII devices.
Incomplete data were obtained by phone or e-mail and
integrated.Participants
Subjects treated with CSII for at least 1 year were
consecutively enrolled among people who attendeddiabetes outpatient clinics between September 2015 and
October 2016. Exclusion criteria were previous diagnosis of
dementia or psychosis and pregnancy in progress. Before
enrolment, informed consent was obtained from each
participant. The study was approved by the ethical com-
mittee of each centre and registered on ClinicalTrials.gov
(NCT 02620917). Procedures complied with the ethical
standards of the institutional and national committees on
human experimentation and with the Helsinki Declaration
of 1975.
Measures
Information on standard clinical variables (i.e. serum
HbA1c, total cholesterol, high-density lipoprotein [HDL]
cholesterol, triglycerides and creatinine), demographic
data (i.e. age, gender, type of diabetes, duration of diabetes,
duration of treatment with CSII and body mass index)
and presence of hypertension and chronic diabetic com-
plications (i.e. retinopathy, nephropathy and vasculopathy
[cerebral, cardiac and peripheral]) was derived from local
clinical management systems. The mean HbA1c level of
participants from the year before the study was calculated.
Information on pump characteristics, use of advanced
pump functions (i.e. different bolus types, bolus calculator
and temporary basal rates), days of sensor use and fre-
quency of self-monitoring of blood glucose was obtained
from insulin pumps or glucometers or recovered from
CGM receivers and was reported in the questionnaire.
Participants were asked to record the number of SH
episodes experienced during the year preceding enrolment
in the study, and the frequency of episodes was expressed
as the cumulative number of SH episodes per participant.
For adult participants, an SH episode was defined as an
event requiring assistance and the administration of
carbohydrates (CHOs) or glucagon [15]. For paediatric par-
ticipants, the SH episode referred to an event associated
with coma, seizures or neurological symptoms requiring
parenteral treatment. The number of diabetic ketoacidosis
(DKA), defined as acidosis and hyperglycaemia, and the
number of visits to the emergency room for acutemetabolic
complications of diabetes were collected from medical re-
cords. Information about the organisation of each centre
included the number of people with T1DM, start of CSII
treatment, team composition (physicians, nurses, dieticians
and psychologists) and around-the-clock availability.
Statistical analysis
Continuous data were expressed as median and inter-
quartile range (IQR). Categorical data were compared
between groups using the chi-square test, whereas
Table 1 Clinical characteristics of study participants.
Variable Total <18 years 18 years
Number of participants 6623 1025 5598
Type of diabetes:
type 1 6543 (98.8) 1025 (100) 5518 (98.6)
type 2 80 (1.2) 0 (0) 80 (1.4)
Age, yearsa 37 (22e49) 14 (11e16) 41 (29e51)
Sex:
Male 2796 (42.2) 497 (48.5) 2299 (41.1)*
Female 3827 (57.8) 528 (51.5) 3299 (58.9)
Duration of
diabetes, yearsa
16 (9e26) 5 (3e8) 19 (12e28)*
Duration of diabetes
at CSII start, yearsa
10 (4e19) 2 (1e4) 12 (6e21)*
Duration of CSII, yearsa 5 (2e8) 2 (1e4) 5 (3e8)*
Blood glucose
tests, n/daya
5.2
(4.0e6.0)
6.1
(6.0e7.0)
5.0 (4.0e6.0)**
Type of device:b
CSII 4206 (64.1) 606 (59.1) 3600 (65.0)***
SAP 2360 (35.9) 419 (40.9) 1941 (35.0)
SAP: sensor use,
days/montha,c
15 (7e24) 21 (10e30) 15 (7e21)*
Data are presented as n (%) or amedian (IQR), where appropriate.
Data not available for. b57 patients and. c84 patients.
*p < 0.0001 for <18 years.
**p < 0.05 for <18 years.
***p < 0.0005 for <18 years.
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ManneWhitney or KruskaleWallis test. All tests were two
sided, and a p value less than 0.05 was considered to be
significant. A linear mixed-effect regression model was
used to identify the predictors of HbA1c among clinically
relevant variables (i.e. age, duration of diabetes, duration
of CSII treatment, type of device, use of sensor-based
treatment, CHO counting and use of advanced pump
functions) that account for the centre’s effects. The centre
was included in the model as a random effect because
participant outcomes were expected to differ from centre
to centre, possibly owing to differences among centres
instead of differences among participants who present at
different centres. Statistical analysis was performed using
R 3.3.2 (The R Foundation for Statistical Computing,
Vienna, Austria) [16].
Results
Study participants and centres
Italy has 272 diabetes care centres that use CSII for treat-
ment. Of them, 93 were included in the study e 21 offering
paediatric care and 72 offering adult care e caring for 6623
patients.
In 41% of the adult care centres, the caring team
composed of physician, dietician and nurse, whereas 71%
of the paediatric centres had a team composed of physi-
cian, nurse, dietician and psychologist. Among the centres,
71% offering adult care and 86% offering paediatric care
were available around the clock.
Demographic and clinical data are presented in Table 1.
Most participants who received CSII treatment had T1DM
(98.8%) and were older than 18 years. Compared to pae-
diatric participants, adults had longer CSII use and were
more frequently female, likely for pump use during preg-
nancy. Blood glucose levels were checked less often for
adult participants than paediatric participants (median
blood glucose tests per day: 5.0 [IQR Z 4.0e5.0] vs 6.1
[IQR Z 6.0e7.0]; p < 0.05).
Chronic complications of diabetes (i.e. retinopathy and
microalbuminuria) and hypertension were more prevalent
among adult participants (Supplementary Table 1). Total
cholesterol, HDL-cholesterol, triglycerides and creatinine
were in the normal range across the different age groups
(Supplementary Table 2).
Use of devices
Irrespective of age, 4263 (64.3%) participants used a con-
ventional insulin pump and 2360 (35.7%) of them used a
pump with an associated or integrated CGM system (SAP).
Among participants who used a SAP, a glucose sensor
was used, on average, 15 days per month (IQR Z 7e24);
785 participants (33.2%) used the sensor less than 10 days
per month, 739 (31.3%) of them used 10e19 days per
month and 836 (35.5%) of them used 20 or more days per
month. The rate of sensor use was higher in subjects less
than 18 years of age (Table 1), with the highest rate amongparticipants 0e5 years old (median: 30 days per month
[IQR Z 25.0e30.0]).
Most participants, whether paediatric or adult, utilized
the advantages of advanced pump features: 81.2% of par-
ticipants used temporary basal, 82.2% used bolus options,
56.5% used the bolus calculator and 75.9% used CHO
counting. The prevalence was greater among participants
who used SAPs than among those who used a conven-
tional pump (temporary basal: 84.2% vs 79.1%, p < 0.0001;
bolus options: 89.2% vs 77.8%, p < 0.0001; bolus calculator:
72.5% vs 64.3%, p < 0.0001; and CHO counting: 81.8% vs
72.2%, p < 0.0001).Metabolic control
Median HbA1c during the year before enrolment in the
study was 60.0 mmol/mol (7.6%) and tended to be lower in
participants aged 6e12 years (Supplementary Table 2).
Male participants had lower HbA1c than female partici-
pants (58.5 [IQR Z 53.0e67.0] mmol/mol or 7.5% [IQR
7.1%e8.3%] vs 60.0 [IQR Z 54.0e68.0] mmol/mol or 7.6%
[IQR Z 7.1%e8.4%]; p < 0.05).
The median HbA1c level was less than 53.0 mmol/mol
(7.0%) in 23.0% of participants and less than 58.0 mmol/
mol (7.5%) in 42.0% of participants (Fig. 1). Considering that
the target HbA1c level varies between children and adults,
a target of <58.0 mmol/mol (7.5%) was achieved in 43.4%
of participants below 18 years of age, whereas only 23.0%
of adults met the target of <53.0 mmol/mol (7%).
Annual levels of HbA1c were lower in 217 women who
became pregnant in the year before data collection than
the levels of the remaining 3610 female participants (51.0
[IQR Z 45.0e51.0] mmol/mol or 6.8% [IQR Z 6.3%e6.8%]
Figure 1 Distribution of mean glycated haemoglobin levels during the year before the study among 6623 Italian individuals treated with
continuous subcutaneous insulin infusion.
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8.4%]; p < 0.0001).
CHO counting and use of advanced pump functionswere
associated with lower HbA1c levels (Fig. 2). Participants
who used SAP had a lower HbA1c level than thosewho used
the conventional pump (58.0 [IQRZ 52.0e66.0] mmol/mol
or 7.5% [IQRZ 6.9%e8.2%] vs 60.0 [IQRZ 54.0e67.0]mmol/
mol or 7.6% [IQR Z 7.1%e8.3%]; p < 0.0001). In addition,
participants who used a sensor more than 20 days per
month had a lower HbA1c level than those who used it less
than 20 days permonth (58.0 [IQRZ 51.0e65.0] mmol/mol
or 7.5% [IQR Z 6.8%e8.1%] vs 59.0 [IQR Z 53.0e66.0]
mmol/mol or 7.6% [IQRZ 7.0%e8.2%]; pZ 0.0008).
The HbA1c level was lower in adult and paediatric par-
ticipants who were monitored by a team composed of
physician, nurse, dietician and psychologist than in those
monitored without a psychologist (58.5 [IQRZ 53.0e66.0]
mmol/mol or 7.5% [IQR Z 7%e8.2%] vs 60.0
[IQR Z 54.0e68.5] mmol/mol or 7.6% (IQR Z 7.1%e8.4%],
p < 0.0001). The results of the multivariable analysis
revealed that longer duration of diabetes (bZ 0.04; 95%
C.I.Z0.09 to0.01), SAP use (bZ1.47; 95% C.I.Z2.43
to 0.51), sensor use (b Z 0.09; 95% C.I. Z 0.13 to
0.04), bolus option (bZ1.76; 95% C.I.Z2.90 to0.63)
and CHO counting (bZ 2.66; 95% C.I.Z 3.83 to 1.49)
were associated with lower HbA1c levels (Table 2). The
effect of using a bolus calculator on HbA1c levels was nearly
statistically significant (b Z 1.02; 95% C.I. Z 2.09 to
0.06).Acute complications
Concerning metabolic emergencies in the previous year,
5.0% of participants at least one SH episode, 2.6% reported
an episode of ketoacidosis and 3.5% reported a visit to the
emergency room for either reason.SH episodes occurred in 52 of 533 participants with
cardiovascular disease and in 243 of 5471 participants
without cardiovascular disease (9.8% vs 4.4%, p < 0.0001).
They also occurred more frequently in adults than
in participants aged less than 18 years (5.6% vs 2.1%,
p < 0.0001), especially among those more than 50 years
old (6.1%). Most participants who reported SH episodes
(200 of 337; 59.3%) experienced one episode per year,
although 63 participants (18.7% among participants with
SH episodes and 0.9% overall) experienced three or more
episodes per year.
Adult participants with HbA1c levels <48.0 mmol/mol
(6.5%) had significantly more SH episodes per year than
those with levels 48.0 mmol/mol (6.5%) (0.17 vs 0.10,
respectively; p < 0.05). No such differences emerged
among paediatric participants. SH episodes were more
frequent in participants who used CGM than those who
did not use (7.3% vs 3.9%, p < 0.0001).
Occurrence of ketoacidosis differed across age groups:
12.1% among participants 0e5 years old, 2.0% among those
6e12 years old, 4.1% among those 13e17 years old, 2.6%
among those 18e50 years old and 1.8% among those older
than 50 years (p Z 0.0003). HbA1c level was 64.0
(IQR Z 57.0e75.0) mmol/mol or 8.0% (IQR Z 7.4%e9.0%)
among participants who experienced episodes of ketoa-
cidosis and 60.0 (IQR Z 53.0e67.0) mmol/mol or 7.6%
(IQRZ 7.0%e8.4%) among those who did not (p < 0.0001).Discussion
We analysed metabolic control and acute and chronic dia-
betic complications in a cohort of Italianpaediatric and adult
individuals with diabetes mellitus who were treated with
CSII. Participants belonged to 16 of the 19 regions of Italy.
We found that 43% of paediatric and 23% of adult in-
dividuals achieved age-specific HbA1c targets. Concerning
Figure 2 Median glycated haemoglobin levels during the year before the study according to the use of advanced pump functions and CHO counting
(*p < 0.0001). Non-users of the bolus calculator include only participants who count carbohydrates.
Insulin pump therapy in Italy 339adults, our data agree with the US T1D Exchange clinic
registry, but considering the paediatric population, the
fraction on target in Italy is almost twofold than that in the
United States [17]. The difference in treatment between
adults and younger people could have different reasons.
Adults could be started on CSII with higher HbA1c level
compared to paediatric individuals, who began CSII mostly
to improve their quality of life. Alternatively, paediatric
individuals could be benefitted from a more complete
caring time or a better use of new technologies.
CGM use in Italy covers only 16 days per month, and our
questionnaire did not specifically investigate the reasons
for suboptimal CGM. We speculate that the limited
coverage may stem from the fact that the national health-
care system does not completely cover sensor costs.
Moreover, because CGM technology is relatively novel,
training in its use could be insufficient. Interestingly, in
contrast to other studies addressing CGM, the rate of sensor
use in our population was greater in the paediatric section,
especially below the age of 12 years, a finding likely due to
parents’ motivation and active role in diabetesTable 2 Multivariable analysis of HbA1c.
Regression coefficient
(with 95% C.I.)
p value
Age, years 0.01 (0.05 to 0.02) 0.33
Duration of diabetes, years 0.05 (0.09 to 0.01) 0.03
Duration of CSII, years 0.06 (0.03 to 0.16) 0.19
Type of device: SAP vs CSII 1.47 (2.43 to 0.51) 0.003
Sensor use, days/month 0.09 (0.13 to 0.04) 0.0001
Temporary basal: yes vs no 0.74 (1.78 to 0.31) 0.17
Bolus options: yes vs no 1.76 (2.90 to 0.63) 0.002
CHO counting: yes vs no 2.66 (3.83 to 1.49) <0.0001
Bolus calculator: yes vs no 1.02 (2.09 to 0.06) 0.06
The regression coefficients represent (i) the change in HbA1c ac-
cording to a change in 1 unit of the continuous predictor or (ii) the
change in HbA1c that is associated with the first category with re-
gard to the second category of the binary predictor.management. Conversely, the rate of sensor use among
participants aged 12e17 years was very low (15 days per
month). In any case, our data indicate that CGM use is
associated with a significantly lower HbA1c level and
confirm existing evidence that the benefit of CGM relates to
the frequency of its use [18]. In this study, SH episodes (0.1
episodes per participant per year) were few compared to
both real-world data and data from RCTs (Refs. [17] and
[19e21], respectively). In our sample, the frequency of SH
episodes was greater among participants using a glucose
sensor. A possible explanation is that CGM is recommended
for persons with disabling hypoglycaemia despite optimal
CSII use. Pumps with a low-glucose suspend (LGS) or pre-
dictive low-glucose suspend (PLGS) system can be expected
to reduce further the risk of SH episodes. However,
although 35.9% of participants used SAP therapy, we do not
know which type of instrument they used (i.e. with or
without an LGS or PLGS function), and thus, we cannot
speculate further about this point.
Adults with HbA1c levels less than 48.0 mmol/mol (6.5%)
exhibited significantly more SH episodes than those with
HbA1c levels greater than 48.0 mmol/mol, which confirms
that tight glycaemic control increases the risk of hypo-
glycaemia. Among paediatric participants, no correlation
emerged between SH episodes and HbA1c levels, which
confirms the results of a recent Italianmulticentre study [22].
Participants who experienced SH episodes had diabetes
for longer duration than those who had not experienced
(20 years [IQR Z 13e28] vs 15 years [IQR Z 9e25];
p < 0.0001). An increase in the frequency of SH episodes
with increased age and duration of diabetes was also
observed in the US T1D Exchange clinic registry [17].
Increased hypoglycaemia unawareness or greater glucose
variability could explain this finding.
Participants with cardiovascular disease had signifi-
cantly more episodes of hypoglycaemia than those
without cardiovascular disease. A possible explanation is
that participants with cardiovascular complications were
340 G. Lepore et al.older (57 [IQRZ 48e65] years vs 35 [IQRZ 22e46] years;
p < 0.0001) and had diabetes for longer duration
(31 [IQR Z 20e40] years vs 15 [IQR Z 9e24] years;
p < 0.0001), which confirms the idea that individuals with
diabetes and cardiovascular disease represent a particu-
larly fragile subgroup with a greater propensity to exhibit
metabolic derangement.
We found that DKA is a problem for some participants.
Because the risk for DKA was higher in participants with
HbA1c levels greater than 64.0 mmol/mol (8.0%), poor
compliance with diabetes treatment could have contrib-
uted to their increased risk for DKA.
The HbA1c level was lower in participants who were
monitored by a team comprising physician, nurse, dieti-
cian and psychologist than those who were monitored by
a team without psychologist. However, the difference,
albeit statistically significant, might not be clinically rele-
vant. Complete diabetes care teams are associated with a
superior use of technology, fewer dropouts, increased CGM
and advanced bolus use [14], but many centres, especially
the smallest ones, have a lack of personnel. In most
adult care centres, teams have no psychologist, although
psychological support is an important part of regular
follow-up.
Our study had several limitations. First, only approxi-
mately 30.0% of the Italian diabetes care centres that use
CSII participated. Our results, however, appear to be
representative of the situation across the country because
centre and patient characteristics were similar to those of
a previous survey that reported data of 79.8% of Italian
people with diabetes who were treated with CSII [14].
We did not have a reference group of individuals treated
with MDI; nevertheless, a partial comparison is possible
with AMD-Annals [23], which have reported routine clin-
ical data of a network of diabetes clinics. In the last report
concerning 28,000 individuals with T1DM (84.5% treated
with MDI), the mean HbA1c level was 65.0  16.0 mmol/
mol (8.1  1.5%). Only 22.3% of MDI-treated individuals
reached the HbA1c target of less than 53.0 mmol/mol
(7.0%), whereas 44.5% showed HbA1c levels greater than
64.0 mmol/mol (8.0%) compared to 29.8% in our study.
Another major limitation of the study is that the
number of SH episodes experienced during the year before
enrolment was based on recall, which obviously implies
inaccuracies, although most people with T1DM have a
good recall of SH episodes over a 1-year period [24].
Finally, because the study was cross-sectional, no con-
clusions can be drawn about the effect of CSII on chronic
diabetic complications [25].
Conclusions
We provide an overview of the metabolic control and
frequency of acute complications of diabetes in Italian
individuals treated with CSII. Mean HbA1c levels were
satisfactory, but only 43% of children and 23% of adults
achieved their age-specific HbA1c target levels. Better
metabolic control was associated with CHO counting, use
of advanced pump functions, compliance with sensor use,pregnancy in the year before the study and longer duration
of diabetes. The low frequency of SH episodes confirms the
positive effect on hypoglycaemia.
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